Galvus (vildagliptin) - DPP-IV Inhibitor / Oral Antidiabetic Agent

 

Key Data:

Drug (Brand / Generic)
Galvus (vildagliptin)
Company / Licensee
Novartis
Therapy Class
DPP-IV inhibitor
Product Description
Inhibits action of DPP-IV, so delaying degradation of GLP-1
Current Indication
Type 2 diabetes
Market Sector
Diabetes
Development Status
Approved Europe; pre-registration US



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
Features
White Papers
Jobs & Careers
Industry News
Gallery
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development